Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study.

Yip AG, Green RC, Huyck M, Cupples LA, Farrer LA; MIRAGE Study Group.

BMC Geriatr. 2005 Jan 12;5:2.

2.

Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer's disease.

Wiebusch H, Poirier J, Sévigny P, Schappert K.

Hum Genet. 1999 Feb;104(2):158-63.

PMID:
10190327
3.

Cholesteryl ester transfer protein polymorphism D442G associated with a potential decreased risk for Alzheimer's disease as a modifier for APOE epsilon4 in Chinese.

Chen DW, Yang JF, Tang Z, Dong XM, Feng XL, Yu S, Chan P.

Brain Res. 2008 Jan 2;1187:52-7. Epub 2007 Nov 26.

PMID:
18036514
4.

APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study.

Huang W, Qiu C, von Strauss E, Winblad B, Fratiglioni L.

Arch Neurol. 2004 Dec;61(12):1930-4. Erratum in: Arch Neurol. 2005 Mar;62(3):453.

PMID:
15596614
5.

Apolipoprotein E-associated risk for Alzheimer's disease in the African-American population is genotype dependent.

Sahota A, Yang M, Gao S, Hui SL, Baiyewu O, Gureje O, Oluwole S, Ogunniyi A, Hall KS, Hendrie HC.

Ann Neurol. 1997 Oct;42(4):659-61.

PMID:
9382479
6.

Head injury and the risk of AD in the MIRAGE study.

Guo Z, Cupples LA, Kurz A, Auerbach SH, Volicer L, Chui H, Green RC, Sadovnick AD, Duara R, DeCarli C, Johnson K, Go RC, Growdon JH, Haines JL, Kukull WA, Farrer LA.

Neurology. 2000 Mar 28;54(6):1316-23.

PMID:
10746604
7.

Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment.

Devanand DP, Pelton GH, Zamora D, Liu X, Tabert MH, Goodkind M, Scarmeas N, Braun I, Stern Y, Mayeux R.

Arch Neurol. 2005 Jun;62(6):975-80.

PMID:
15956169
8.

Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD.

Qiu C, Winblad B, Fastbom J, Fratiglioni L.

Neurology. 2003 Sep 9;61(5):655-60.

PMID:
12963757
9.

Association between apolipoprotein E polymorphism and Alzheimer disease in Tehran, Iran.

Raygani AV, Zahrai M, Raygani AV, Doosti M, Javadi E, Rezaei M, Pourmotabbed T.

Neurosci Lett. 2005 Feb 25;375(1):1-6. Epub 2004 Nov 26.

PMID:
15664112
10.

APOE genotype and cholesterol levels in lewy body dementia and Alzheimer disease: investigating genotype-phenotype effect on disease risk.

Borroni B, Grassi M, Costanzi C, Archetti S, Caimi L, Padovani A.

Am J Geriatr Psychiatry. 2006 Dec;14(12):1022-31. Epub 2006 Sep 6.

PMID:
16956959
11.

Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotype.

Davidson Y, Gibbons L, Pritchard A, Hardicre J, Wren J, Tian J, Shi J, Stopford C, Julien C, Thompson J, Payton A, Thaker U, Hayes AJ, Iwatsubo T, Pickering-Brown SM, Pendleton N, Horan MA, Burns A, Purandare N, Lendon CL, Neary D, Snowden JS, Mann DM.

J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):515-7.

12.

A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease.

Pasqualetti P, Bonomini C, Dal Forno G, Paulon L, Sinforiani E, Marra C, Zanetti O, Rossini PM.

Aging Clin Exp Res. 2009 Apr;21(2):102-10.

PMID:
19448381
13.

APOE epsilon4 and Alzheimer's disease: positive association in a Colombian clinical series and review of the Latin-American studies.

Jacquier M, Arango D, Villareal E, Torres O, Serrano ML, Cruts M, Montañes P, Cano C, Rodriguez MN, Serneels S, Van Broeckhoven C.

Arq Neuropsiquiatr. 2001 Mar;59(1):11-7. Review.

14.

The CDC2 I-G-T haplotype associated with the APOE epsilon4 allele increases the risk of sporadic Alzheimer's disease in Sicily.

Bosco P, Caraci F, Copani A, Spada RS, Sortino MA, Salluzzo R, Salemi M, Nicoletti F, Ferri R.

Neurosci Lett. 2007 Jun 4;419(3):195-8. Epub 2007 Apr 8.

PMID:
17498878
15.

GAB2 gene does not modify the risk of Alzheimer's disease in Spanish APOE 4 carriers.

Ramirez-Lorca R, Boada M, Saez ME, Hernandez I, Mauleon A, Rosende-Roca M, Martinez-Lage P, Gutierrez M, Real LM, Lopez-Arrieta J, Gayan J, Antunez C, Gonzalez-Perez A, Tarraga L, Ruiz A.

J Nutr Health Aging. 2009 Mar;13(3):214-9.

PMID:
19262956
16.

Apolipoprotein E epsilon4 and age at onset of sporadic and familial Alzheimer disease in Caribbean Hispanics.

Olarte L, Schupf N, Lee JH, Tang MX, Santana V, Williamson J, Maramreddy P, Tycko B, Mayeux R.

Arch Neurol. 2006 Nov;63(11):1586-90.

PMID:
17101827
17.

CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.

Smach MA, Charfeddine B, Lammouchi T, Harrabi I, Ben Othman L, Dridi H, Bennamou S, Limem K.

Neurosci Lett. 2008 Aug 1;440(2):145-9. doi: 10.1016/j.neulet.2008.05.076. Epub 2008 May 24.

PMID:
18555606
18.

Association between apolipoprotein E epsilon4 allele and apathy in probable Alzheimer's disease.

Monastero R, Mariani E, Camarda C, Ingegni T, Averna MR, Senin U, Camarda R, Mecocci P.

Acta Psychiatr Scand. 2006 Jan;113(1):59-63. Erratum in: Acta Psychiatr Scand. 2005 Dec;112(6):481.

PMID:
16390371
19.

Reduced hippocampal volume in non-demented carriers of the apolipoprotein E epsilon4: relation to chronological age and recognition memory.

Lind J, Larsson A, Persson J, Ingvar M, Nilsson LG, Bäckman L, Adolfsson R, Cruts M, Sleegers K, Van Broeckhoven C, Nyberg L.

Neurosci Lett. 2006 Mar 20;396(1):23-7. Epub 2006 Jan 6.

PMID:
16406347
20.

The urokinase-type plasminogen activator polymorphism PLAU_1 is a risk factor for APOE-epsilon4 non-carriers in the Italian Alzheimer's disease population and does not affect the plasma Abeta(1-42) level.

Pesaresi M, Batelli S, Prato F, Polito L, Lovati C, Scarpini E, Quadri P, Mariani C, Albani D, Forloni G.

Neurobiol Dis. 2007 Mar;25(3):609-13. Epub 2006 Dec 15.

PMID:
17174555

Supplemental Content

Support Center